InvestmentMay 21, 2026, 05:32 PM
Immix Biopharma Prices $150M Underwritten Offering of Common Stock
AI Summary
Immix Biopharma, Inc. announced the pricing of an underwritten public offering of 16,778,524 shares of its common stock at $8.94 per share. The offering is expected to generate gross proceeds of $150 million, with estimated net proceeds of approximately $140.65 million. The company plans to use these funds for NXC-201 development, working capital, and general corporate purposes, which is anticipated to extend its operational runway into mid-2028.
Key Highlights
- Immix Biopharma priced an underwritten public offering of 16,778,524 shares of its common stock.
- The public offering price is set at $8.94 per share.
- The offering is expected to generate gross proceeds of $150 million.
- Estimated net proceeds are approximately $140.65 million after deducting expenses.
- Proceeds will be used to fund NXC-201 development, working capital, and general corporate purposes.
- The company expects the funds to meet operational needs into mid-2028.
- Morgan Stanley & Co. LLC is acting as the lead book-running manager for the offering.
Price Impact
More from IMMX